Pages that link to "Q37064418"
Jump to navigation
Jump to search
The following pages link to I f inhibition with ivabradine : electrophysiological effects and safety (Q37064418):
Displaying 50 items.
- Ivabradine as adjuvant treatment for chronic heart failure (Q24185982) (← links)
- Ivabradine as adjuvant treatment for chronic heart failure (Q24201614) (← links)
- Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization (Q24605881) (← links)
- Ivabradine, coronary artery disease, and heart failure: beyond rhythm control (Q26865770) (← links)
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study (Q28291971) (← links)
- Pharmacodynamic effects of ivabradine, a negative chronotropic agent, in healthy cats (Q30431487) (← links)
- Pacemaker current inhibition in experimental human cardiac sympathetic activation: a double-blind, randomized, crossover study. (Q33163797) (← links)
- HCN Channel Targets for Novel Antidepressant Treatment. (Q34557298) (← links)
- TRIP8b is required for maximal expression of HCN1 in the mouse retina (Q35084850) (← links)
- Echocardiographic assessment of pressure volume relations in heart failure and valvular heart disease: using imaging to understand physiology. (Q37121912) (← links)
- Shox2 is essential for the differentiation of cardiac pacemaker cells by repressing Nkx2-5. (Q37222054) (← links)
- The Role of Ivabradine in the Management of Angina Pectoris (Q37298004) (← links)
- Focus on ivabradine: a new heart rate-controlling drug (Q37390737) (← links)
- If Inhibition in Cardiovascular Diseases (Q37798963) (← links)
- Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease (Q37923966) (← links)
- Stable angina pectoris: antianginal therapies and future directions (Q37924086) (← links)
- Exploring HCN channels as novel drug targets (Q37957655) (← links)
- Ivabradine: an intelligent drug for the treatment of ischemic heart disease (Q38060459) (← links)
- Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction (Q38062592) (← links)
- 'Inappropriate' sinus tachycardia: does the 100 beats per min cut-off matter? (Q38086846) (← links)
- Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties (Q38127568) (← links)
- Antagonist molecules in the treatment of angina (Q38139089) (← links)
- Antiarrhythmic drugs 2013: state of the art. (Q38139281) (← links)
- Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure (Q38142792) (← links)
- An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure. (Q38174653) (← links)
- Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure (Q38235948) (← links)
- Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4. (Q38547097) (← links)
- Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation (Q38547436) (← links)
- Ivabradine for the treatment of chronic heart failure (Q38769814) (← links)
- Experimental and early investigational drugs for angina pectoris (Q38803136) (← links)
- Heart rate reduction in coronary artery disease and heart failure (Q38844531) (← links)
- An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF). (Q38973132) (← links)
- Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis. (Q39176836) (← links)
- Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management (Q39317320) (← links)
- Gabapentin Modulates HCN4 Channel Voltage-Dependence. (Q41485000) (← links)
- Concomitant administration of simvastatin with ivabradine in contrast to metoprolol intensifies slowing of heart rate in normo- and hypercholesterolemic rats (Q41888327) (← links)
- Heart rate reduction: an old and novel candidate heart failure therapy. (Q42335255) (← links)
- New developments in the antiarrhythmic therapy of atrial fibrillation (Q42792403) (← links)
- Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). (Q43247698) (← links)
- Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat. (Q46222726) (← links)
- Ivabradine and nightmares: a previously unreported adverse reaction (Q48296314) (← links)
- Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias (Q48567516) (← links)
- Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study (Q51006365) (← links)
- The role of Shox2 in SAN development and function (Q51817893) (← links)
- Ivabradine on aortic stiffness in patients with heart failure. (Q53600304) (← links)
- Ivabradine and the SIGNIFY conundrum. (Q54546642) (← links)
- Role of ivabradine in management of stable angina in patients with different clinical profiles. (Q54961020) (← links)
- Concomitant administration of different doses of simvastatin with ivabradine influence on PAI-1 and heart rate in normo- and hypercholesterolaemic rats. (Q55687041) (← links)
- Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT (Q88146880) (← links)
- Acute effect of ivabradine on heart rate and myocardial oxygen consumption in dogs with asymptomatic mitral valve degeneration (Q88670672) (← links)